Skip to main content

Day: April 11, 2023

KP Tissue to Release its Financial Results and those of Kruger Products Inc. for the First Quarter of 2023

MISSISSAUGA, Ontario, April 11, 2023 (GLOBE NEWSWIRE) — KP Tissue Inc. (“KPT”) (TSX:KPT), which holds an interest in Kruger Products Inc. will release the financial results for KPT and Kruger Products Inc for the first quarter of 2023 on Thursday, May 11, 2023 before the market opens. KPT will hold its conference call the same day at 8:30 a.m. Eastern Time. Details of the Conference Call Via telephone: 1-888-396-8049 or 416-764-8646Via the internet at: www.kptissueinc.com Presentation material referenced during the conference call will be available at www.kptissueinc.com Conference Call Rebroadcast A rebroadcast of the conference call will be available until midnight, May 18, 2023 by dialing 1-877-674-7070 or 416-764-8692 and entering passcode 181690. The replay of the webcast will remain available on the web site until midnight,...

Continue reading

US Nuclear’s Unique Monitors Can Help With Mitigation in Case of any Release From Fukushima’s 880 Tons of Radioactive Debris

LOS ANGELES, CA, April 11, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – The next large earthquake could bring very bad news- new images from inside the Fukushima nuclear reactor show significant damage to the foundation and have sparked new concerns about the safety of the melted down reactor, containment of the highly radioactive fuel, and the daunting task of ultimately decommissioning and cleaning up the disaster.  Earthquake resistance of the structure and leakage of the radioactive material are the main concerns, and US Nuclear’s (OTC-QB: UCLE) novel real-time radiation in water monitors could prove pivotal in monitoring the situation and any potential releases of radioactive contamination. The latest findings were conducted by TEPCO at the end of March using underwater robotic probes to survey the primary containment chamber...

Continue reading

Hepsiburada Regains Compliance with Nasdaq Minimum Bid Price Requirement

ISTANBUL, Türkiye, April 11, 2023 (GLOBE NEWSWIRE) — D-MARKET Electronic Services & Trading (d/b/a “Hepsiburada”) (NASDAQ: HEPS), a leading Turkish e-commerce platform (referred to herein as “Hepsiburada” or the “Company”), announced today that on April 6, 2023 it received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company has regained compliance with the minimum bid price requirement of US$1.00 per share under Nasdaq Listing Rule 5450(a)(1). For the 10 consecutive business days prior to the receipt of the said letter, the closing bid price of the Company’s American depositary shares (“ADSs”), each representing one Class B ordinary share of the Company, had been trading at US$1.00 per ADS or greater. Nasdaq indicated within the letter that this matter is...

Continue reading

ReShape Lifesciences® Receives Notice of Allowance for U.S. Patent Related to its Obalon® Balloon System

SAN CLEMENTE, Calif., April 11, 2023 (GLOBE NEWSWIRE) — ReShape Lifesciences™ (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the company has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application 16/792,094, entitled, “Systems and Methods for Determining Failure of Intragastric Devices,” related to its Obalon® Balloon System. The patent will cover additional claims for the Obalon® Balloon System and is expected to provide protection into at least January 2031, without accounting for a potential Patent Term Extension (PTE). “Allowance of this patent significantly strengthens our intellectual property portfolio around innovations for the Obalon Intragastric Balloon System,” stated Paul F. Hickey, President and...

Continue reading

Veru Announces Preclinical Study Results that Demonstrate Sabizabulin Inhibits Poxviruses

Sabizabulin inhibited the cell release and cell-to-cell spread of poxvirus in a preclinical study Veru further expands study of sabizabulin for the treatment of poxvirus acute respiratory distress syndrome (ARDS) Company plans pre-Investigational New Drug (IND) meeting with FDA to evaluate sabizabulin under the Animal Rule regulatory pathway for treatment of smallpox virus outbreak MIAMI, FL, April 11, 2023 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology, today announced results from a preclinical in vitro study evaluating the effects of sabizabulin against prototypical poxvirus, vaccinia virus, which demonstrated that sabizabulin prevented both the release of poxvirus from infected cells and the spread...

Continue reading

TRILLION ENERGY SPUDS FIFTH WELL AT SASB GAS FIELD DEVELOPMENT

Bayhanli–2 gas well spudded at East Ayazli targeting significant Proved Reserves Vancouver, B.C., April 11, 2023 (GLOBE NEWSWIRE) — Trillion Energy International Inc. (“Trillion” or the “Company”) (CSE: TCF) (OTCQB: TRLEF) (Frankfurt: Z62) is pleased to announce the spudding of the Bayhanli-2 well at the SASB Gas field, Black Sea Turkiye. Bayhanli-2 is the fifth gas well in our multi-well drilling program at the SASB gas field development. The well targets a previously discovered gas pool, which was never previously produced, through a long reach directional well bore to enable production. The Bayhanli gas pool is a significant target and may likely require additional wells in the future to fully produce the economic reserves. Upon completion, the Bayhanli-2 well is expected to reach a total measured depth of 3,400 metres...

Continue reading

Apollomics Co-Founder and President, Sanjeev Redkar, Ph.D., to Speak at 23rd Annual R. Bryan Miller Symposium

Dr. Redkar to discuss importance of HGF/cMET pathway, which can play critical role in origin of several cancers FOSTER CITY, Calif., April 11, 2023 (GLOBE NEWSWIRE) — Apollomics Inc. (Nasdaq: APLM), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that the company’s Co-Founder and President, Sanjeev Redkar, MBA, Ph.D., will speak at the 23rd Annual R. Bryan Miller Symposium, an event exploring the interface of chemical biology and organic chemistry in honor of Professor R. Bryan Miller, at the University of California, Davis on April 14, 2023. Dr. Redkar will deliver the presentation, titled, “The HGF/cMet Pathway in Cancer – Early Development to Clinical Evidence,” at 11 a.m. PST at the UC Davis Conference...

Continue reading

NuLegacy Gold Improves Discovery Prospects

Enrolls Robert Leonardson RENO, Nev., April 11, 2023 (GLOBE NEWSWIRE) — NuLegacy Gold is pleased to report enrolling the renowned Mr. Robert Leonardson, BSGE, MSG, Michigan Tech thus adding another member of the original “Goldrush discovery” team, with a view to improving the prospects of discovering a major Carlin gold deposit on our flagship 108 sq. km Red Hill property in the Cortez gold-trend of Nevada. One of Mr. Leonardson’s greatest contributions while at Barrick Gold Corp. was as a mentor. Charles Weakly, NuLegacy’s Exploration Manager, and the recently enrolled consultants Nancy Richter (Feb. 22, 2023) and Mike Penick (Mar. 21, 2023) were among the many whose exploration success benefitted from Bob’s mentoring. Mr. Leonardson’s career spans over 55 years across the Western United States, Eastern Canada, and Chile, exploring...

Continue reading

Cellebrite to Release First-Quarter 2023 Financial Results on May 10, 2023

PETAH TIKVA, Israel and TYSONS CORNER, Va., April 11, 2023 (GLOBE NEWSWIRE) — Cellebrite (NASDAQ: CLBT), a global leader in Digital Intelligence (“DI”) solutions for the public and private sectors, today announced it will report its first-quarter 2023 financial results before market open on Wednesday, May 10, 2023. Later that same morning, Cellebrite will host a live conference call and webcast to review the Company’s financial results for the first quarter of 2023 and discuss its full-year 2023 outlook. Pertinent details include:Date:   Wednesday, May 10, 2023Time:   8:30 a.m. ETCall-In Number:   203-518-9814Conference ID:   CLBTQ123Event URL:   https://investors.cellebrite.com/events/event-details/cellebrite-q1-23-earningsLive Webcast URL:   https://edge.media-server.com/mmc/p/u58372yqIn conjunction...

Continue reading

Shockwave Medical Completes Acquisition of Neovasc

SANTA CLARA, CA, April 11, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – Shockwave Medical, Inc. (NASDAQ: SWAV) (“Shockwave”), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, today announced the completion of its previously announced acquisition of Neovasc Inc. (“Neovasc”). The Neovasc Reducer System (the “Reducer”) is a first-of-its-kind technology to address refractory angina. Refractory angina is a chronic condition in which a patient suffers chest pain that cannot be controlled by conventional therapies. It is estimated that each year, in the U.S. and the E.U. alone, up to 300,000 new patients with obstructive coronary disease who are ineligible for conventional revascularization experience refractory angina, despite guideline-directed medical therapy. In addition,...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.